Safety of Celecoxib in Patients With Crohn's Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Crohn's Disease
Interventions
DRUG

Celebrex

"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."

DRUG

placebo

placebo PO BID for either the first eight weeks or the last eight weeks of the study.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Shadyside Hospital Foundation

OTHER

collaborator

Pfizer

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00177866 - Safety of Celecoxib in Patients With Crohn's Disease | Biotech Hunter | Biotech Hunter